RNAi in Man: Initial Results from ALN-VSP Phase I Clinical Trial

RNAi in Man: Initial Results from ALN-VSP Phase I Clinical Trial

In January 2011, Jared Gollob, M.D., Senior Director of Clinical Research at Alnylam, presented important clinical data from our ALN-VSP Phase I trial, demonstrating that RNAi can be harnessed in man using systemically delivered RNAi therapeutics.



These data provide significant human proof of concept for our efforts in advancing RNAi therapeutics as a potential new class of medicines.  As our systemic delivery platform is employed across our clinical and pre-clinical pipeline, these results are critical in Alnylam’s overall efforts in advancing this innovative technology to patients.



SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.